# Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

> **NCT04443062** · PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 58 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-617

## Key facts

- **NCT ID:** NCT04443062
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2025-04-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04443062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04443062, "Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04443062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*